GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Circio Holding ASA (OSL:CRNA) » Definitions » Future Policy Benefits

Circio Holding ASA (OSL:CRNA) Future Policy Benefits


View and export this data going back to 2016. Start your Free Trial

What is Circio Holding ASA Future Policy Benefits?

Future Policy Benefits only applies to insurance companies.


Circio Holding ASA (OSL:CRNA) Business Description

Traded in Other Exchanges
Address
Vollsveien 19, Lysaker, Oslo, NOR, 1366
Circio Holding ASA is a clinical-stage company. It is focused on developing and commercializing immuno-oncology therapies to target treatment-resistant solid tumors. Its product candidate, ONCOS-102, is a genetically modified oncolytic adenovirus, which has been engineered to infect cancer cells and activate the immune system to fight cancer. It includes the development and implementation with the purpose of developing targeted immunotherapy treatments for cancer patients.